miércoles, 14 de junio de 2023

FDA Approves EPKINLY (Epcoritamab-bysp) for Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario